As an adjuvant for peptide vaccines, NVT/SM-LNP enhances antigen-specific CD4+ and CD8+ T cell responses and demonstrates potent therapeutic efficacy across subcutaneous, orthotopic, and metastatic TC-1 and B16-OVA tumor models, while also reducing viral titers in a chronic LCMV infection model. This evidence concerns the gene CD8A and neoplasm.